Drug profile

Here's what the FDA CVM extract says about Monensin Granulated

The CVM extract lists 11 reports for Monensin Granulated, a lower-volume entry. Species, reactions, and outcomes are below.

#2479 of 2,679
by report volume (all drugs)
11
adverse-event reports
54.5%
death-coded share
Cattle
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Monensin Granulated ranks #2412 of 2679 by total reports (11). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2412
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Monensin Granulated has 11 reports now versus 11 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Monensin Granulated changes

Signature read: Monensin Granulated's 54.5% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
6
Deaths Reported
54.5%
Death-coded share of reports

Active Ingredients

Monensin Granulated

Administration Routes

OralUnknown

Species Affected

Cattle 11

Most Affected Breeds

Aberdeen Angus 5
Cattle (other) 4
Cattle (unknown) 1
Unknown 1

Most Reported Reactions

Lack of efficacy - NOS 7
Death 5
Necropsy performed 2
Pneumonia 2
Respiratory signs 2
Lung oedema 1
Bronchopneumonia 1
Found dead 1
Bloated 1
Respiratory tract disorder NOS 1
Digestive tract disorder NOS 1
Liver abscess 1

Outcome Breakdown

Died
6 (50.0%)
Outcome Unknown
6 (50.0%)

Monensin Granulated: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Where to go from here

  • Before drawing conclusions from this number, read why death-coded share is not the same thing as a mortality rate. Understanding adverse events
  • Browse the full drug directory to compare report counts across products. All drugs

Correlation in adverse-event counts is not causation; consult a veterinarian before making a decision from this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Monensin Granulated (#2479 of 2,679 by report volume); death-coded 54.5%. PlainBreed drug row · death-coded share stamp 54.5% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →